Sort   by:  
 Page size 
UnknownSymptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
Not available
S-EPMC10052317 | biostudies-literature
UnknownViral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.
Not available
S-EPMC11793053 | biostudies-literature
UnknownEmergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
Not available
S-EPMC9675946 | biostudies-literature
UnknownSafety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC11566225 | biostudies-literature
UnknownResults of the two incidence screenings in the National Lung Screening Trial.
Not available
S-EPMC4307922 | biostudies-literature
UnknownSafety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Not available
S-EPMC10134004 | biostudies-literature
UnknownA dyadic approach to the delineation of diagnostic entities in clinical genomics.
Not available
S-EPMC7820621 | biostudies-literature
UnknownSafety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
Not available
S-EPMC10579289 | biostudies-literature
UnknownELFN1 deficiency: The mechanistic basis and phenotypic spectrum of a neurodevelopmental disorder with epilepsy.
Not available
S-EPMC12260708 | biostudies-literature
UnknownPost-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Not available
S-EPMC11381616 | biostudies-literature
Sort   by:  
 Page size